Rimegepant
- Product Name
- Rimegepant
- CAS No.
- 1289023-67-1
- Chemical Name
- Rimegepant
- Synonyms
- BMS-927711;BMS 927711;CS-2806;BHV-3000;BMS 92771;Rimegepan;Remazepam;Ramazepam;Rimegepant;BMS927711;BMS 927711
- CBNumber
- CB42645135
- Molecular Formula
- C28H28F2N6O3
- Formula Weight
- 534.56
- MOL File
- 1289023-67-1.mol
Rimegepant Property
- Density
- 1.45±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- A crystalline solid
- pka
- 12.03±0.20(Predicted)
- color
- White to off-white
- InChIKey
- KRNAOFGYEFKHPB-ANJVHQHFSA-N
- SMILES
- N1(C(O[C@H]2C3=NC=CC=C3[C@@H](N)[C@H](C3=CC=CC(F)=C3F)CC2)=O)CCC(N2C3=CC=CN=C3NC2=O)CC1
N-Bromosuccinimide Price
- Product number
- 26338
- Product name
- Rimegepant
- Packaging
- 1mg
- Price
- $43
- Updated
- 2023/06/20
- Product number
- 26338
- Product name
- Rimegepant
- Packaging
- 5mg
- Price
- $189
- Updated
- 2023/06/20
- Product number
- 26338
- Product name
- Rimegepant
- Packaging
- 10mg
- Price
- $334
- Updated
- 2023/06/20
- Product number
- 26338
- Product name
- Rimegepant
- Packaging
- 25mg
- Price
- $678
- Updated
- 2023/06/20
- Product number
- R517100
- Product name
- Rimegepant
- Packaging
- 500mg
- Price
- $15225
- Updated
- 2021/12/16
Rimegepant Chemical Properties,Usage,Production
Description
Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).
Uses
Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for the treatment of migraine.
in vivo
Rimegepant (BMS-927711) has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical properties, and shows dose-dependent activity in a primate model of CGRP-induced facial blood flow[1]. The ratios of the mean AUC (0-24 h) values for Rimegepant (BMS-927711) (60, 100, and 300 mg/kg) in the DBS matrix, compare with plasma, are 0.5-0.6 across all doses in rats. Results from this study suggest a strong correlation of Rimegepant concentrations between rat plasma and rat blood (DBS)[2].
Rimegepant Preparation Products And Raw materials
Raw materials
Preparation Products
Rimegepant Suppliers
- Tel
- --
- Fax
- --
- standards@synzeal.com
- Country
- India
- ProdList
- 6514
- Advantage
- 58
View Lastest Price from Rimegepant manufacturers
- Product
- Rimegepant 1289023-67-1
- Price
- US $5.00-0.50/KG
- Min. Order
- 1KG
- Purity
- 99% hplc
- Supply Ability
- 500TONS
- Release date
- 2025-06-05
- Product
- Rimegepant 1289023-67-1
- Price
- US $0.00-0.00/g
- Min. Order
- 10g
- Purity
- 99%
- Supply Ability
- 5kgs
- Release date
- 2024-11-05
- Product
- Rimegepant 1289023-67-1
- Price
- US $0.00/KG
- Min. Order
- 0.1KG
- Purity
- 98%
- Supply Ability
- 1000KGS
- Release date
- 2023-07-14